ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000974

Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

Identifieur interne : 000974 ( PascalFrancis/Corpus ); précédent : 000973; suivant : 000975

Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

Auteurs : Junchao Tong ; Paul S. Fitzmaurice ; Lee Cyn Ang ; Yoshiaki Furukawa ; Mark Gunman ; Stephen J. Kish

Source :

Annals of neurology [ 0364-5134 ] ; 2004.

RBID : Pascal:04-0448985

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dopamine, Atrophie multisystématisée, Paralysie, Système nerveux pathologie.

English descriptors

KwdEn :
- Dopamine, Multiple system atrophy, Nervous system diseases, Paralysis, Parkinson disease.

Abstract

The dopamine D₁ receptor is considered to participate in levodopa's antiparkinsonian action and levodopa-induced dyskinesias. We examined the functional status of the D₁ receptor in brain of patients with Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Dopamine-stimulated adenylyl cyclase activity was significantly increased in putamen (+43%) and frontal cortex (+52%) in PD, normal in PSP, but decreased by 47% in putamen in MSA. The supersensitive dopamine D₁ receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0364-5134`
A02	`01`			`@0 ANNED3`
A03		`1`		`@0 Ann. neurol.`
A05				`@2 55`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy`
A11	`01`	`1`		`@1 TONG (Junchao)`
A11	`02`	`1`		`@1 FITZMAURICE (Paul S.)`
A11	`03`	`1`		`@1 ANG (Lee Cyn)`
A11	`04`	`1`		`@1 FURUKAWA (Yoshiaki)`
A11	`05`	`1`		`@1 GUNMAN (Mark)`
A11	`06`	`1`		`@1 KISH (Stephen J.)`
A14	`01`			`@1 Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health @2 Toronto @3 CAN @Z 1 aut. @Z 2 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Division of Neuropathology, London Health Science Center, University of Western Ontario @2 London @3 GBR @Z 3 aut.`
A14	`03`			`@1 Movement Disorder Research Laboratory, Center for Addiction and Mental Health @2 Toronto, Ontario @3 CAN @Z 4 aut.`
A20				`@1 125-129`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16555 @5 354000113877770180`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 20 ref.`
A47	`01`	`1`		`@0 04-0448985`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The dopamine D₁ receptor is considered to participate in levodopa's antiparkinsonian action and levodopa-induced dyskinesias. We examined the functional status of the D₁ receptor in brain of patients with Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Dopamine-stimulated adenylyl cyclase activity was significantly increased in putamen (+43%) and frontal cortex (+52%) in PD, normal in PSP, but decreased by 47% in putamen in MSA. The supersensitive dopamine D₁ receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy.
C02	`01`	`X`		`@0 002B17`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 02`
C03	`02`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 02`
C03	`02`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 02`
C03	`03`	`X`	`FRE`	`@0 Atrophie multisystématisée @2 NM @5 04`
C03	`03`	`X`	`ENG`	`@0 Multiple system atrophy @2 NM @5 04`
C03	`03`	`X`	`SPA`	`@0 Atrofia multisistematizada @2 NM @5 04`
C03	`04`	`X`	`FRE`	`@0 Paralysie @5 07`
C03	`04`	`X`	`ENG`	`@0 Paralysis @5 07`
C03	`04`	`X`	`SPA`	`@0 Parálisis @5 07`
C03	`05`	`X`	`FRE`	`@0 Système nerveux pathologie @5 10`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 10`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 10`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso central @5 38`
C07	`03`	`X`	`FRE`	`@0 Catécholamine @5 39`
C07	`03`	`X`	`ENG`	`@0 Catecholamine @5 39`
C07	`03`	`X`	`SPA`	`@0 Catecolamina @5 39`
C07	`04`	`X`	`FRE`	`@0 Neurotransmetteur @5 40`
C07	`04`	`X`	`ENG`	`@0 Neurotransmitter @5 40`
C07	`04`	`X`	`SPA`	`@0 Neurotransmisor @5 40`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 41`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
C07	`07`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 43`
C07	`07`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`07`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
C07	`08`	`X`	`FRE`	`@0 Trouble moteur @5 45`
C07	`08`	`X`	`ENG`	`@0 Motor system disorder @5 45`
C07	`08`	`X`	`SPA`	`@0 Trastorno motor @5 45`
C07	`09`	`X`	`FRE`	`@0 Trouble neurologique @5 46`
C07	`09`	`X`	`ENG`	`@0 Neurological disorder @5 46`
C07	`09`	`X`	`SPA`	`@0 Trastorno neurológico @5 46`
N21				`@1 250`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 04-0448985 INIST
ET :	Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
AU :	TONG (Junchao); FITZMAURICE (Paul S.); ANG (Lee Cyn); FURUKAWA (Yoshiaki); GUNMAN (Mark); KISH (Stephen J.)
AF :	Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health/Toronto/Canada (1 aut., 2 aut., 5 aut., 6 aut.); Division of Neuropathology, London Health Science Center, University of Western Ontario/London/Royaume-Uni (3 aut.); Movement Disorder Research Laboratory, Center for Addiction and Mental Health/Toronto, Ontario/Canada (4 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2004; Vol. 55; No. 1; Pp. 125-129; Bibl. 20 ref.
LA :	Anglais
EA :	The dopamine D₁ receptor is considered to participate in levodopa's antiparkinsonian action and levodopa-induced dyskinesias. We examined the functional status of the D₁ receptor in brain of patients with Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Dopamine-stimulated adenylyl cyclase activity was significantly increased in putamen (+43%) and frontal cortex (+52%) in PD, normal in PSP, but decreased by 47% in putamen in MSA. The supersensitive dopamine D₁ receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy.
CC :	002B17
FD :	Parkinson maladie; Dopamine; Atrophie multisystématisée; Paralysie; Système nerveux pathologie
FG :	Encéphale pathologie; Système nerveux central; Catécholamine; Neurotransmetteur; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Trouble moteur; Trouble neurologique
ED :	Parkinson disease; Dopamine; Multiple system atrophy; Paralysis; Nervous system diseases
EG :	Cerebral disorder; Central nervous system; Catecholamine; Neurotransmitter; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Motor system disorder; Neurological disorder
SD :	Parkinson enfermedad; Dopamina; Atrofia multisistematizada; Parálisis; Sistema nervioso patología
LO :	INIST-16555.354000113877770180
ID :	04-0448985

Links to Exploration step

Pascal:04-0448985

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy</title>
<author><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ang, Lee Cyn" sort="Ang, Lee Cyn" uniqKey="Ang L" first="Lee Cyn" last="Ang">Lee Cyn Ang</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Neuropathology, London Health Science Center, University of Western Ontario</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation><inist:fA14 i1="03"><s1>Movement Disorder Research Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gunman, Mark" sort="Gunman, Mark" uniqKey="Gunman M" first="Mark" last="Gunman">Mark Gunman</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0448985</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0448985 INIST</idno>
<idno type="RBID">Pascal:04-0448985</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000974</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy</title>
<author><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ang, Lee Cyn" sort="Ang, Lee Cyn" uniqKey="Ang L" first="Lee Cyn" last="Ang">Lee Cyn Ang</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Neuropathology, London Health Science Center, University of Western Ontario</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation><inist:fA14 i1="03"><s1>Movement Disorder Research Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gunman, Mark" sort="Gunman, Mark" uniqKey="Gunman M" first="Mark" last="Gunman">Mark Gunman</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine</term>
<term>Multiple system atrophy</term>
<term>Nervous system diseases</term>
<term>Paralysis</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dopamine</term>
<term>Atrophie multisystématisée</term>
<term>Paralysie</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The dopamine D<sub>1</sub>
 receptor is considered to participate in levodopa's antiparkinsonian action and levodopa-induced dyskinesias. We examined the functional status of the D<sub>1</sub>
 receptor in brain of patients with Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Dopamine-stimulated adenylyl cyclase activity was significantly increased in putamen (+43%) and frontal cortex (+52%) in PD, normal in PSP, but decreased by 47% in putamen in MSA. The supersensitive dopamine D<sub>1</sub>
 receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0>
</fA01>
<fA02 i1="01"><s0>ANNED3</s0>
</fA02>
<fA03 i2="1"><s0>Ann. neurol.</s0>
</fA03>
<fA05><s2>55</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TONG (Junchao)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FITZMAURICE (Paul S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ANG (Lee Cyn)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FURUKAWA (Yoshiaki)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GUNMAN (Mark)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KISH (Stephen J.)</s1>
</fA11>
<fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Neuropathology, London Health Science Center, University of Western Ontario</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Movement Disorder Research Laboratory, Center for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>125-129</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16555</s2>
<s5>354000113877770180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0448985</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The dopamine D<sub>1</sub>
 receptor is considered to participate in levodopa's antiparkinsonian action and levodopa-induced dyskinesias. We examined the functional status of the D<sub>1</sub>
 receptor in brain of patients with Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Dopamine-stimulated adenylyl cyclase activity was significantly increased in putamen (+43%) and frontal cortex (+52%) in PD, normal in PSP, but decreased by 47% in putamen in MSA. The supersensitive dopamine D<sub>1</sub>
 receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Atrophie multisystématisée</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Multiple system atrophy</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Atrofia multisistematizada</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Paralysie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Paralysis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parálisis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Trouble moteur</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Motor system disorder</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Trastorno motor</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>46</s5>
</fC07>
<fN21><s1>250</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0448985 INIST</NO>
<ET>Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy</ET>
<AU>TONG (Junchao); FITZMAURICE (Paul S.); ANG (Lee Cyn); FURUKAWA (Yoshiaki); GUNMAN (Mark); KISH (Stephen J.)</AU>
<AF>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health/Toronto/Canada (1 aut., 2 aut., 5 aut., 6 aut.); Division of Neuropathology, London Health Science Center, University of Western Ontario/London/Royaume-Uni (3 aut.); Movement Disorder Research Laboratory, Center for Addiction and Mental Health/Toronto, Ontario/Canada (4 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2004; Vol. 55; No. 1; Pp. 125-129; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<EA>The dopamine D<sub>1</sub>
 receptor is considered to participate in levodopa's antiparkinsonian action and levodopa-induced dyskinesias. We examined the functional status of the D<sub>1</sub>
 receptor in brain of patients with Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Dopamine-stimulated adenylyl cyclase activity was significantly increased in putamen (+43%) and frontal cortex (+52%) in PD, normal in PSP, but decreased by 47% in putamen in MSA. The supersensitive dopamine D<sub>1</sub>
 receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy.</EA>
<CC>002B17</CC>
<FD>Parkinson maladie; Dopamine; Atrophie multisystématisée; Paralysie; Système nerveux pathologie</FD>
<FG>Encéphale pathologie; Système nerveux central; Catécholamine; Neurotransmetteur; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Trouble moteur; Trouble neurologique</FG>
<ED>Parkinson disease; Dopamine; Multiple system atrophy; Paralysis; Nervous system diseases</ED>
<EG>Cerebral disorder; Central nervous system; Catecholamine; Neurotransmitter; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Motor system disorder; Neurological disorder</EG>
<SD>Parkinson enfermedad; Dopamina; Atrofia multisistematizada; Parálisis; Sistema nervioso patología</SD>
<LO>INIST-16555.354000113877770180</LO>
<ID>04-0448985</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000974 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000974 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0448985
   |texte=   Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri